Aurobindo Pharma Ltd. — Regulatory Filings 2021

Nov 10, 2021

==> picture [128 x 61] intentionally omitted <==

November 10, 2021

	ToListing Department,NATIONAL STOCK EXCHANGE OF INDIA LIMITEDExchange Plaza,Bandra Kurla Complex, Bandra (E),MUMBAI -400 051Company Code No. AUROPHARMA	ToThe Corporate Relations DepartmentBSE LIMITEDPhiroz Jeejeebhoy Towers,25thfloor, Dalal Street,MUMBAI -400 001Company Code No. 524804

Dear Sirs/Madam,

Re: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Company has received a communication from the USFDA classifying the inspection conducted at its Unit I (API) manufacturing facility in Hyderabad, India between August 2 to August 12, 2021 as Official Action Indicated (OAI), keeping the status unchanged.

The Company believes that this inspection classification will not impact the continuing commercial supplies to the US market from this facility.

The Company will be engaging with the regulator and is fully committed in resolving the status of this facility at the earliest.

This may be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Kindly take note of the above information on record.

Yours faithfully, For AUROBINDO PHARMA LIMITED

==> picture [89 x 26] intentionally omitted <==

B. Adi Reddy Company Secretary

==> picture [208 x 15] intentionally omitted <==

==> picture [133 x 10] intentionally omitted <==

==> picture [120 x 9] intentionally omitted <==

==> picture [87 x 9] intentionally omitted <==

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032 Telangana, India. Tel.: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044 E-mail: info@aurobindo.com

Regd. Off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038 T.S., India Tel.: +91 40 2373 6370 / 2374 7340 Fax: +91 40 2374 1080 / 2374 6833